BofA analyst Allen Lutz lowered the firm’s price target on Doximity to $24 from $28 and keeps an Underperform rating on the shares. The firm is reducing its FY24 and FY25 revenue estimates following the company’s quarterly report and believes the revenue multiple may come under further pressure as investors assess the levers to growth.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DOCS: